respiratory diseases

Nemiralisib(GSK-2269557 free base) is an orally available, potent and specific PI3Kδ inhibitor with a pKi of 9.9.Nemiralisib is used for the treatment of respiratory diseases including chronic obstructive pulmonary disease.

L 651896 is a novel leukotriene biosynthesis and 5-lipoxygenase inhibitor for the study of respiratory and cardiovascular diseases.

Bamaquimast (L 0042) is a proton pump inhibitor for the study of asthma-like immune system disorders and respiratory diseases.

GAL-021 sulfate is a BKCa channel blocker that inhibits the analgesic effects of opioids and is used in the study of respiratory control diseases.

uk-50001 is a phosphodiesterase (PDE) 4 inhibitor that can be used for many diseases, especially inflammation, allergies, respiratory diseases, disorders and conditions and wounds.

Imitrodast is a small molecule thromboxane A2 synthase (TXA2 synthase) inhibitor for the treatment of immune system disorders, respiratory disorders, and cardiovascular diseases, and can be used in studies of arterial thrombosis, asthma, and coronary vasospasm.

GSK2292767 FA is a potent and selective inhibitor of PI3Kδ (pIC50 : 10.1).GSK2292767 FA is more than 500-fold more selective than other PI3K isoforms.GSK2292767 FA can be used in the study of respiratory diseases.

PF-4348235 HCl (β2AR M-receptor agonist-2 HCl) is a muscarinic M3 receptor antagonist (Ki: 0.73 nM) and β2 adrenergic receptor agonist (MABA, EC50: 3.7 nM). PF-4348235 HCl is also a bronchial BM213 acetate is a bronchodilator used to study cardiovascular and respiratory diseases such as chronic obstructive pulmonary disease (COPD).

(E Z)-Sivopixant ((E Z)-S-600918) is a potent P2X3 receptor antagonist with an IC50 of 4 nM, suitable for respiratory diseases research.

Oxolamine citrate (AF-438 citrate) is a cough suppressant that is able to be used as a generic drug in many jurisdictions.

Tylosin tartrate, a macrolide antibiotic, is approved for the control of mycoplasmosis in poultry.

Ambroxol (NA-872) is a secretolytic agent used in the treatment of respiratory diseases associated with viscid or excessive mucus. It is the active ingredient of Mucosolvan, Lasolvan or Mucoangin. The substance is a mucoactive drug with several properties including secretolytic and secretomotoric actions that restore the physiological clearance mechanisms of the respiratory tract which play an important role in the body's natural defense mechanisms. It stimulates synthesis and release of surfactant by type II pneumocytes. Surfactants act as an anti-glue factor by reducing the adhesion of mucus to the bronchial wall, in improving its transport and in providing protection against infection and irritating agents.

Tylosin (Tylosine) is a macrolide antibiotic obtained from cultures of Streptomyces fradiae. The drug is effective against many microorganisms in animals but not in humans.

Bisphenol A is an endogenous metabolic compound of phenols and is widely used in the production of epoxy resins and polycarbonate plastics. It is reproductive, developmental and systemic toxicant and is often classified as an endocrine disruptor. It has been linked to many diseases, including respiratory disease, cardiovascular disease, diabetes, kidney disease, obesity and reproductive disorders.

ONO-6126 has anti-inflammatory activity and can inhibit Phosphodiesterase and PDE4 in the treatment of respiratory diseases.This compound is unstable in powder form and other related salt forms are recommended.

Lascufloxacin, a potent and orally active fluoroquinolone antibacterial agent, holds potential for the treatment of various infectious diseases, including lower respiratory tract infections. It effectively inhibits infections caused by a wide range of pathogens, encompassing those resistant to quinolones.

Letosteine (Viscotiol) is an orally active, effective, and safe expectorant that can be used in the study of acute or chronic respiratory diseases, for example, bronchopulmonary disease. Letosteine dissolves bronchial mucus and reduces symptoms of respiratory inflammation and restores gas exchanges and natural defense mechanisms in the lung[1] [2] [3].

Fenspiride hydrochloride (Decaspiride) , an oxazolidinone spiro compound, is a drug used in the therapy of certain respiratory diseases. It is approved for use in Russia for the therapy of chronic and acute inflammatory diseases of ENT organs and the respiratory tract (like sinusitis, tracheobronchitis, otitis, laryngitis, and rhinopharyngitis), and for maintenance therapy of asthma.

Substance P Receptor Antagonist 1 has potential applications in treating gastrointestinal disorders, inflammatory diseases, respiratory conditions, and central nervous system disorders.

CS-003 free base (CS-003) is a triple tachykinin receptor antagonist with high affinity for human (neurokinin) NK1, NK2 and NK3 receptors, with Ki values of 2.3 nM and 0.54 nM, respectively And 0.74 nM. CS-003 free base (CS-003) has therapeutic effects on

Pamufetinib mesylate (TAS-115 mesylate) is a potent vascular endothelial growth factor receptor (VEGFR) antagonist and hepatocyte growth factor receptor (c-Met) inhibitor used in the study of cancer and respiratory diseases.

Rispenzepine is a novel antagonist of muscarinic acetylcholine receptors (mAChRs), selectively targeting the M1 and M3 receptor subtypes, and can be used in the treatment of immune system disorders, infections, and respiratory diseases.

Mavelertinib (PF-06747775) is an orally available, selective and potent EGFR tyrosine kinase (EGFR TKI) inhibitor with inhibitory effects on T790M L858R and T790M Del, and can be used in the study of oncology and respiratory diseases.

CGP 45715A (irukostat) is a potent peptide-leukotriene antagonist used to treat respiratory diseases by antagonizing the bronchial constriction, mucus secretion, and inflammatory effects of these leukotrienes.